Cite
Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa
MLA
Bella Madan, et al. “Recombinant Factor VIIa Analog in the Management of Hemophilia with Inhibitors: Results from a Multicenter, Randomized, Controlled Trial of Vatreptacog Alfa.” Journal of Thrombosis and Haemostasis, vol. 12, no. 8, July 2014, pp. 1244–53. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....2cda7dc222225026f6ef334db58bc053&authtype=sso&custid=ns315887.
APA
Bella Madan, A. Sori, Midori Shima, Pantep Angchaisuksiri, Hideji Hanabusa, A. Kupesiz, T. Andreeva, Kaan Kavakli, W. Tsay, D. Obzut, M. Shen, Aleksandar Savic, Philip Kuriakose, Michael Recht, Marina Economou, Shipra Kaicker, Laszlo Nemes, A. Weltermann, Afshin Ameri, … Zoltán Boda. (2014). Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa. Journal of Thrombosis and Haemostasis, 12(8), 1244–1253.
Chicago
Bella Madan, A. Sori, Midori Shima, Pantep Angchaisuksiri, Hideji Hanabusa, A. Kupesiz, T. Andreeva, et al. 2014. “Recombinant Factor VIIa Analog in the Management of Hemophilia with Inhibitors: Results from a Multicenter, Randomized, Controlled Trial of Vatreptacog Alfa.” Journal of Thrombosis and Haemostasis 12 (8): 1244–53. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....2cda7dc222225026f6ef334db58bc053&authtype=sso&custid=ns315887.